AR056506A1 - Sal glucuronato de un compuesto derivado de piperazina - Google Patents

Sal glucuronato de un compuesto derivado de piperazina

Info

Publication number: AR056506A1
Authority: AR; Argentina
Prior art keywords: piperazina; compound derived; glucuronate salt; salt; present
Prior art date: 2005-09-12

Application number

ARP060103944A

Other languages

English (en)

Spanish (es)

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-12

Filing date

2006-09-11

Publication date

2007-10-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37603202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056506(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-11 Application filed by Wyeth Corp filed Critical Wyeth Corp

2007-10-10 Publication of AR056506A1 publication Critical patent/AR056506A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ARP060103944A 2005-09-12 2006-09-11 Sal glucuronato de un compuesto derivado de piperazina AR056506A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71616705P	2005-09-12	2005-09-12

Publications (1)

Publication Number	Publication Date
AR056506A1 true AR056506A1 (es)	2007-10-10

Family

ID=37603202

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP060103944A AR056506A1 (es)	2005-09-12	2006-09-11	Sal glucuronato de un compuesto derivado de piperazina

Country Status (20)

Country	Link
US (1)	US7595310B2 (zh)
EP (1)	EP1940830A1 (zh)
JP (1)	JP2009507921A (zh)
KR (1)	KR20080045285A (zh)
CN (1)	CN101287730B (zh)
AR (1)	AR056506A1 (zh)
AU (1)	AU2006291058B2 (zh)
BR (1)	BRPI0615853A2 (zh)
CA (1)	CA2620755A1 (zh)
EA (1)	EA014942B1 (zh)
GT (1)	GT200600414A (zh)
IL (1)	IL189809A0 (zh)
MY (1)	MY144782A (zh)
NO (1)	NO20081809L (zh)
PE (1)	PE20070433A1 (zh)
SA (1)	SA06270329B1 (zh)
TW (1)	TW200800974A (zh)
UA (1)	UA95922C2 (zh)
WO (1)	WO2007033191A1 (zh)
ZA (1)	ZA200802310B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200800306A (en)	2005-09-12	2008-01-01	Wyeth Corp	Sustained-release formulation and uses thereof
GT200600414A (es)	2005-09-12	2007-09-20		Sal de glucuranato de compuesto de piperazine
GT200600416A (es)	2005-09-12	2007-09-20		Sales salicilato y gentisato de un compuesto de piperazina
ES2617671T3 (es)	2007-05-11	2017-06-19	Richter Gedeon Nyrt.	Forma cristalina de un derivado de carbamoil ciclohexano
HUP0700353A2 (en)	2007-05-18	2008-12-29	Richter Gedeon Nyrt	Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en)	2007-12-03	2011-01-25	Richter Gedeon Nyrt.	Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
MY156288A (en)	2008-07-16	2016-01-29	Richter Gedeon Nyrt	Pharmaceutical formulations containing dopamine receptor ligands.
HU230067B1 (hu)	2008-12-17	2015-06-29	Richter Gedeon Nyrt	Új piperazin só és eljárás előállítására
HUP0800766A2 (en)	2008-12-18	2010-11-29	Richter Gedeon Vegyeszet	Process for the preparation of piperazine derivatives
HUP0800765A2 (en)	2008-12-18	2010-11-29	Richter Gedeon Nyrt	A new process for the preparation of piperazine derivatives and their hydrochloric salts
WO2014031162A1 (en)	2012-08-20	2014-02-27	Forest Laboratories Holdings Limited	Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en)	2016-07-08	2022-03-15	Richter Gedeon Nyrt.	Industrial process for the preparation of cariprazine
US11547707B2 (en)	2019-04-10	2023-01-10	Richter Gedeon Nyrt.	Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4438119A (en)	1982-12-23	1984-03-20	Mead Johnson & Company	Method for alleviation of extrapyramidal motor disorders
US4687772A (en)	1986-10-07	1987-08-18	Bristol-Myers Company	Method for improvement of short term memory
US4771053A (en)	1987-03-02	1988-09-13	Bristol-Myers Company	Method for alleviation of primary depressive disorders
US5162375A (en)	1988-05-06	1992-11-10	Beecham Group P.L.C.	Treatment of neuronal degeneration with 5HT1A agonists
DE4135551A1 (de)	1991-08-31	1993-03-04	Schering Ag	Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en)	1991-08-31	1998-10-20	Bayer Aktiengesellschaft	Ipsapirone for the treatment of alzheimer's disease by improving memory
US5716960A (en) *	1995-01-13	1998-02-10	U.S. Bioscience Inc. And Individuals	Crystalline trimetrexate salts and the process for making the same
SE9900190D0 (sv)	1999-01-22	1999-01-22	Astra Ab	New compounds
DE19730989A1 (de) *	1997-07-18	1999-01-21	Merck Patent Gmbh	Piperazin-Derivate
AU736596B2 (en) *	1997-07-25	2001-08-02	H. Lundbeck A/S	Indole and 2,3-dihydroindole derivatives, their preparation and use
HN1999000146A (es)	1998-09-21	2000-11-11	Pfizer Prod Inc	Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
CZ298533B6 (cs) *	1999-08-23	2007-10-31	Solvay Pharmaceuticals B. V.	Deriváty fenylpiperazinu, zpusob jejich prípravy a farmaceutické prostredky s jejich obsahem
PL356605A1 (en)	2000-01-19	2004-06-28	Akzo Nobel N.V.	Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
AR032712A1 (es) *	2001-02-21	2003-11-19	Solvay Pharm Bv	Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
US7514438B2 (en)	2003-08-13	2009-04-07	Amgen, Inc.	Melanin concentrating hormone receptor antagonist
EP1592688A2 (en)	2003-12-18	2005-11-09	Teva Pharmaceutical Industries Ltd.	Polymorphic form b2 of ziprasidone base
GT200600414A (es)	2005-09-12	2007-09-20		Sal de glucuranato de compuesto de piperazine
GT200600416A (es) *	2005-09-12	2007-09-20		Sales salicilato y gentisato de un compuesto de piperazina
TW200800306A (en)	2005-09-12	2008-01-01	Wyeth Corp	Sustained-release formulation and uses thereof

2006
- 2006-09-08 GT GT200600414A patent/GT200600414A/es unknown
- 2006-09-11 AR ARP060103944A patent/AR056506A1/es not_active Application Discontinuation
- 2006-09-11 PE PE2006001091A patent/PE20070433A1/es not_active Application Discontinuation
- 2006-09-11 TW TW095133454A patent/TW200800974A/zh unknown
- 2006-09-12 JP JP2008531254A patent/JP2009507921A/ja active Pending
- 2006-09-12 EP EP06803440A patent/EP1940830A1/en not_active Withdrawn
- 2006-09-12 BR BRPI0615853-6A patent/BRPI0615853A2/pt not_active IP Right Cessation
- 2006-09-12 SA SA06270329A patent/SA06270329B1/ar unknown
- 2006-09-12 US US11/519,756 patent/US7595310B2/en not_active Expired - Fee Related
- 2006-09-12 KR KR1020087008818A patent/KR20080045285A/ko not_active Ceased
- 2006-09-12 AU AU2006291058A patent/AU2006291058B2/en not_active Ceased
- 2006-09-12 CA CA002620755A patent/CA2620755A1/en not_active Abandoned
- 2006-09-12 EA EA200800810A patent/EA014942B1/ru not_active IP Right Cessation
- 2006-09-12 WO PCT/US2006/035517 patent/WO2007033191A1/en not_active Ceased
- 2006-09-12 CN CN2006800382372A patent/CN101287730B/zh not_active Expired - Fee Related
- 2006-09-12 MY MYPI20080551A patent/MY144782A/en unknown
- 2006-12-09 UA UAA200804630A patent/UA95922C2/ru unknown
2008
- 2008-02-27 IL IL189809A patent/IL189809A0/en unknown
- 2008-03-11 ZA ZA200802310A patent/ZA200802310B/xx unknown
- 2008-04-14 NO NO20081809A patent/NO20081809L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
SA06270329B1 (ar)	2010-06-15
AU2006291058A1 (en)	2007-03-22
CA2620755A1 (en)	2007-03-22
MY144782A (en)	2011-11-15
BRPI0615853A2 (pt)	2011-05-31
ZA200802310B (en)	2008-12-31
EA014942B1 (ru)	2011-04-29
EP1940830A1 (en)	2008-07-09
US20070254876A1 (en)	2007-11-01
IL189809A0 (en)	2008-08-07
GT200600414A (es)	2007-09-20
TW200800974A (en)	2008-01-01
US7595310B2 (en)	2009-09-29
PE20070433A1 (es)	2007-04-24
AU2006291058B2 (en)	2011-09-08
JP2009507921A (ja)	2009-02-26
CN101287730B (zh)	2012-03-07
UA95922C2 (en)	2011-09-26
KR20080045285A (ko)	2008-05-22
WO2007033191A1 (en)	2007-03-22
NO20081809L (no)	2008-04-14
EA200800810A1 (ru)	2008-10-30
CN101287730A (zh)	2008-10-15

Publication	Publication Date	Title
BRPI0519316B8 (pt)	2021-06-29	composição aquosa herbicida, e, processo para a preparação de uma composição
MA38248A1 (fr)	2016-12-30	Compositions pesticides et procédés associés
ECSP099684A (es)	2009-11-30	Aril pirrolidinas insecticidas
PH12013500365A1 (en)	2014-09-08	Anti-infective agents and uses thereof
WO2013023732A3 (de)	2013-04-11	Ternesit als anreger für latent-hydraulische und puzzolanische materialien
UA112281C2 (uk)	2016-08-25	Стабільні інсектицидні композиції і способи їх отримання
MX2010002902A (es)	2010-06-02	Pirimidinas anti-infecciosas y usos de las mismas.
CY1112511T1 (el)	2015-12-09	Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
CR9223A (es)	2007-11-23	18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
AR056506A1 (es)	2007-10-10	Sal glucuronato de un compuesto derivado de piperazina
UY31274A1 (es)	2009-03-02	Composiciones de recubrimiento electrodepositable que contiene una guanidina ciclica
DOP2006000051A (es)	2006-08-31	Inhibidores de vegf-r2 y métodos
AU2010246102A8 (en)	2015-03-05	Pesticidal compositions
ECSP11010812A (es)	2011-10-31	Complejo de mineral-aminoácido polisacárido
WO2009009041A3 (en)	2009-05-07	Compositions and methods for modulating a kinase cascade
CR10548A (es)	2009-01-27	18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
MX2013002826A (es)	2013-04-05	Composiciones que contienen un insecticida de piripiropeno y una base.
EA201300338A1 (ru)	2013-12-30	Пестицидная и паразитицидная смесь и композиция, которая включает новую кристаллическую модификацию фипронила
UY31688A1 (es)	2009-09-30	Plaguicidas
BRPI0919048B8 (pt)	2022-10-11	Composições pesticidas
CO6571899A2 (es)	2012-11-30	Composición pesticida y su uso
WO2012172438A3 (en)	2013-03-28	Compositions and methods for modulating a kinase
WO2012103391A3 (en)	2014-03-13	Insescticidal composition and processes related thereto
NO20074277L (no)	2007-11-23	Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer
BR112019016208A2 (pt)	2020-04-14	formulação de dissuasão de abuso de anfetamina

Legal Events

Date	Code	Title	Description
2014-12-03	FA	Abandonment or withdrawal